11 June 2021 | Webinar
Advances in basic science, technology and medicine continually create opportunities for new and improved medically assisted reproduction (MAR) therapies.
These may be wholly new types of therapies or improved methodologies for the preparation of existing techniques. While the objective of these changes and novelties is to prepare MAR therapies that are safer, clinically more effective and meet the needs of clinicians and patients, there is always a risk that any change in the processing method can result in harm in the recipient. It is therefore vital that an evaluation of the potential risk of a process is systematically evaluated whenever a significant change is made
The aim of this training webinar is to aid cell and tissue bankers and healthcare professionals in the evaluation of safety, quality and efficacy of MAR therapies, thus providing effective care of their patients.
The generic objectives of this course are:
The targets of this training are:
The course aims to improve the scientific assessment of novel products/processes/clinical indications and associated risks, and promote the correct definition of evaluation protocols to guarantee safe implementation
By the end of this training participants should be able:
11:00 – 11:20 Introduction to EuroGTP methodologies - Ioana Rugescu
11:20 – 12:00 Practical cases - Kelly Tilleman
12:00 – 12:20 Discussion - Inputs from participants and Q&A – Moderator: Jaime Tabera & Richard Lomas
12:20 – 12:30 Impact and continuity of EuroGTP II Project – Rita Piteira
Register here free of charge. Be sure to register early since the number of participants is limited.
Share this page